Stock events for Ceribell, Inc. (CBLL)
Ceribell, Inc.'s stock debuted in October 2024 at $17.00, experienced a sell-off, but has since been trending higher. Ceribell received FDA Breakthrough Device Designation for its LVO Stroke Detection and Monitoring Solution on January 5, 2026. On December 9, 2025, Ceribell received FDA 510(k) clearance for its delirium monitoring solution. Ceribell announced its participation in the 44th Annual J.P. Morgan Healthcare Conference on December 30, 2025. As of February 1, 2026, the stock was trading at $20.61, with a 52-week high of $26.04 and a 52-week low of $10.01.
Demand Seasonality affecting Ceribell, Inc.’s stock price
The provided search results do not contain specific information regarding the demand seasonality for Ceribell, Inc.'s products and services. Demand may be more consistent rather than subject to significant seasonal fluctuations, driven by ongoing patient needs and hospital utilization.
Overview of Ceribell, Inc.’s business
Ceribell, Inc. is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. It operates in the Healthcare sector, specifically the Medical Devices industry, and its primary offering is the Ceribell System, a point-of-care EEG platform for acute care settings. The Ceribell System enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies. It includes disposable headbands with non-invasive electrodes, pocket-sized battery-operated recorders, Clarity, an AI-powered algorithm for real-time EEG interpretation, and an EEG Portal, a cloud-based portal for remote access to EEG data.
CBLL’s Geographic footprint
Ceribell, Inc. is headquartered in Sunnyvale, California, United States, with its operations and focus primarily within the United States.
CBLL Corporate Image Assessment
The provided search results do not contain specific details about Ceribell, Inc.'s brand reputation. The company's focus on scientific innovation, medical advancement, and commitment to environmental sustainability suggests a positive corporate image. Ceribell aims to create a healthier, more sustainable future and plans to assess and disclose its operational emissions, with a goal of achieving net-zero greenhouse gas emissions by 2030.
Ownership
The provided search results do not contain specific details about major institutional and individual owners of Ceribell, Inc.
Ask Our Expert AI Analyst
Price Chart
$18.67
